Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340728 · ClinicalTrials.gov registry record · Phase 3
Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies
A Phase 3 study of Pancreatic Cancer and Unresectable Biliary-pancreatic Malignancies, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02340728 is a Phase 3 study of Pancreatic Cancer and Unresectable Biliary-pancreatic Malignancies that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02340728, a Phase 3 study of Pancreatic Cancer and Unresectable Biliary-pancreatic Malignancies, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effects good and/or bad of combining radiofrequency ablation with placement of a second stent, versus a second stent alone. The investigators will also look at the safety of the combination treatment, and see which treatment is better. In either case, the second stent will be placed inside the existing stent as is done in standard practice when treating a blocked stent for the first time.
Conditions Studied
Interventions
- DEVICE ERCP with SEMS plus radiofrequency ablation
- DEVICE ERCP with SEMS alone (standard of care)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340728
The ClinicalTrials.gov registry entry for NCT02340728 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which ERCP with SEMS plus radiofrequency ablation is the first listed.
NCT02340728 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02340728 about?
NCT02340728 is a clinical study titled "Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies". The purpose of this study is to compare the effects good and/or bad of combining radiofrequency ablation with placement of a second stent, versus a second stent alone. The investigators will also look at the safety of the combination treatment, and see which treatment is better. In either case, the ...
What is the current status of trial NCT02340728?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2019-11.
What conditions does trial NCT02340728 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Unresectable Biliary-pancreatic Malignancies.
What interventions are being tested in trial NCT02340728?
The interventions under investigation include: ERCP with SEMS plus radiofrequency ablation (DEVICE), ERCP with SEMS alone (standard of care) (DEVICE).
Who is sponsoring clinical trial NCT02340728?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02340728 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Explore more on PlainTrial
Pancreatic Cancer
All registered trials for this condition
Unresectable Biliary-pancreatic Malignancies
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.